Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and BEAM in Relapsed/Refractory CD20+ NHL
NCT00521560Phase 2Completed
- Sponsor
- Institut für anwendungsorientierte Forschung und klinische Studien
- Start
- Mar 2006
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by Institut für anwendungsorientierte Forschung und klinische Studien. Started Mar 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00521560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521560.